Autolus Therapeutics plc (AUTL) stock
AUTLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/3020% below fair value
$1.09−0.05 (-4.39%)
Close on Nov 17, 2026Market cap $290.12MP/E –Yield –
Autolus Therapeutics gross margin
Gross margin is gross profit as a percentage of revenue.
Autolus Therapeutics's gross margin for the twelve months ending Jun 30, 2026 was 15.7%. For fiscal 2025 it was -27.8%, against -12.5% the year before.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -27.8% | −15.3 |
| FY2024 | Dec 31, 2024 | -12.5% | −112.5 |
| FY2023 | Dec 31, 2023 | 100.0% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | 55.2% | +72.0 |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | 6.3% | +106.1 |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | -4.3% | +39161.2 |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | -35.1% | −135.1 |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | -16.8% | – |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | -99.9% | – |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | -39165.5% | – |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | 100.0% | – |
See a number that looks wrong?